Steven Elfrink, OmTerra Co-Founder and Psychedelic Somatic Interactional Therapist, is also the Co-Founder of the Psychedelic Somatic Institute (PSI), a psychedelic somatic therapist training organization. He was a participant in the 2015, Phase 1 FDA Pharmacokinetic Study of Psilocybin at UW-Madison that also studied the effects of high-dose psilocybin for adverse reactions. Steven had a first-hand experience of the benefits and shortcomings of the current non-directive model used in psychedelic therapy worldwide. This led him to creating OmTerra and PSI to expand the potential of psychedelic medicines utilizing a somatic focus. Steven brings 30 years of corporate experience in education and marketing to the psychedelic community and gratefully brings to the world his heart-felt passion for the advancement of psychedelic therapy and his commitment to help people who are suffering.
No Records Found
Sorry, no records were found. Please adjust your search criteria and try again.